<?xml version='1.0' encoding='utf-8'?>
<document id="25155930"><sentence text="Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction."><entity charOffset="0-12" id="DDI-PubMed.25155930.s1.e0" text="Voriconazole" /><entity charOffset="17-27" id="DDI-PubMed.25155930.s1.e1" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.25155930.s1.e0" e2="DDI-PubMed.25155930.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s1.e0" e2="DDI-PubMed.25155930.s1.e1" /></sentence><sentence text="To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype"><entity charOffset="39-51" id="DDI-PubMed.25155930.s2.e0" text="voriconazole" /><entity charOffset="120-130" id="DDI-PubMed.25155930.s2.e1" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.25155930.s2.e0" e2="DDI-PubMed.25155930.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s2.e0" e2="DDI-PubMed.25155930.s2.e1" /></sentence><sentence text="" /><sentence text="We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-based regimens (with or without ritonavir)"><entity charOffset="81-93" id="DDI-PubMed.25155930.s4.e0" text="voriconazole" /><entity charOffset="98-108" id="DDI-PubMed.25155930.s4.e1" text="atazanavir" /><entity charOffset="141-150" id="DDI-PubMed.25155930.s4.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25155930.s4.e0" e2="DDI-PubMed.25155930.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s4.e0" e2="DDI-PubMed.25155930.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25155930.s4.e0" e2="DDI-PubMed.25155930.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25155930.s4.e1" e2="DDI-PubMed.25155930.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25155930.s4.e1" e2="DDI-PubMed.25155930.s4.e2" /></sentence><sentence text=" They were managed by assessing their CYP2C19 genotype (CYP2C19*2, rs4244285, G&gt;A, real-time PCR) and therapeutic drug monitoring (HPLC-based validation methods)" /><sentence text="" /><sentence text="Voriconazole exposure was variable but Ctrough levels were above 1000 ng/ml in all patients; one CYP2C19 intermediate metabolizer required lower doses of voriconazole (50 mg twice daily) to obtain satisfactory drug concentrations"><entity charOffset="0-12" id="DDI-PubMed.25155930.s7.e0" text="Voriconazole" /><entity charOffset="154-166" id="DDI-PubMed.25155930.s7.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25155930.s7.e0" e2="DDI-PubMed.25155930.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s7.e0" e2="DDI-PubMed.25155930.s7.e1" /></sentence><sentence text=" Atazanavir and ritonavir plasma levels were moderately reduced (area under the curve: -23 and -26%, respectively); raltegravir exposure seemed increased by voriconazole administration (area under the curve: 2"><entity charOffset="1-11" id="DDI-PubMed.25155930.s8.e0" text="Atazanavir" /><entity charOffset="16-25" id="DDI-PubMed.25155930.s8.e1" text="ritonavir" /><entity charOffset="116-127" id="DDI-PubMed.25155930.s8.e2" text="raltegravir" /><entity charOffset="157-169" id="DDI-PubMed.25155930.s8.e3" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e0" e2="DDI-PubMed.25155930.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e0" e2="DDI-PubMed.25155930.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e0" e2="DDI-PubMed.25155930.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e0" e2="DDI-PubMed.25155930.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e1" e2="DDI-PubMed.25155930.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e1" e2="DDI-PubMed.25155930.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e1" e2="DDI-PubMed.25155930.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e2" e2="DDI-PubMed.25155930.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25155930.s8.e2" e2="DDI-PubMed.25155930.s8.e3" /></sentence><sentence text="5-fold higher) in a single subject" /><sentence text=" Coadministration of atazanavir and voriconazole may be feasible in selected HIV-positive patients; therapeutic drug monitoring and CYP2C19 genotyping may optimize exposure of both drugs"><entity charOffset="21-31" id="DDI-PubMed.25155930.s10.e0" text="atazanavir" /><entity charOffset="36-48" id="DDI-PubMed.25155930.s10.e1" text="voriconazole" /><pair ddi="false" e1="DDI-PubMed.25155930.s10.e0" e2="DDI-PubMed.25155930.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25155930.s10.e0" e2="DDI-PubMed.25155930.s10.e1" /></sentence><sentence text="" /></document>